{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T07:01:04Z","timestamp":1763535664804,"version":"3.37.3"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T00:00:00Z","timestamp":1572998400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T00:00:00Z","timestamp":1572998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","award":["xxxx"],"award-info":[{"award-number":["xxxx"]}],"id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s42000-019-00148-y","type":"journal-article","created":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T15:02:51Z","timestamp":1573052571000},"page":"423-434","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pediatric growth hormone therapy in Greece: analysis of the Hellenic cohort of the GeNeSIS study"],"prefix":"10.1007","volume":"18","author":[{"name":"for the Hellenic GeNeSIS study group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Kosteria","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0442-6231","authenticated-orcid":false,"given":"K.","family":"Aloumanis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Kanaka-Gantenbein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Vlachopapadopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Michalacos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Stamoyannou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Drossinos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Chrousos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,6]]},"reference":[{"key":"148_CR1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1136\/adc.2010.186205","volume":"97","author":"J Kirk","year":"2012","unstructured":"Kirk J (2012) Indications for growth hormone therapy in children. Arch Dis Child 97:63\u201368. https:\/\/doi.org\/10.1136\/adc.2010.186205","journal-title":"Arch Dis Child"},{"key":"148_CR2","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1159\/000452150","volume":"19104","author":"A Grimberg","year":"2016","unstructured":"Grimberg A, DiVall SA, Polychronakos C et al (2016) Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. Horm Res Paediatr 19104:361\u2013397. https:\/\/doi.org\/10.1159\/000452150","journal-title":"Horm Res Paediatr"},{"key":"148_CR3","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-17-0430","volume":"177","author":"CH Gravholt","year":"2017","unstructured":"Gravholt CH, Andersen NH, Conway GS et al (2017) Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur J Endocrinol 177:G1\u2013G70. https:\/\/doi.org\/10.1530\/EJE-17-0430","journal-title":"Eur J Endocrinol"},{"key":"148_CR4","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1210\/jc.2009-0178","volume":"95","author":"J Bell","year":"2010","unstructured":"Bell J, Parker KL, Swinford RD et al (2010) Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab 95:167\u2013177. https:\/\/doi.org\/10.1210\/jc.2009-0178","journal-title":"J Clin Endocrinol Metab"},{"key":"148_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000110474","volume":"68","author":"F Darendeliler","year":"2007","unstructured":"Darendeliler F, Karagiannis G, Wilton P (2007) Headache, idiopathic intracranial hypertension and slipped capital femoral epiphysis during growth hormone treatment: a safety update from the KIGS database. Horm Res Paediatr 68:41\u201347. https:\/\/doi.org\/10.1159\/000110474","journal-title":"Horm Res Paediatr"},{"key":"148_CR6","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1054\/ghir.2000.0175","volume":"10","author":"PE Clayton","year":"2000","unstructured":"Clayton PE, Cowell CT (2000) Safety issues in children and adolescents during growth hormone therapy--a review. Growth Hormon IGF Res 10:306\u2013317. https:\/\/doi.org\/10.1054\/ghir.2000.0175","journal-title":"Growth Hormon IGF Res"},{"key":"148_CR7","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1210\/jc.2015-1002","volume":"100","author":"S Raman","year":"2015","unstructured":"Raman S, Grimberg A, Waguespack SG et al (2015) Risk of neoplasia in pediatric patients receiving growth hormone therapy--a report from the Pediatric Endocrine Society Drug and Therapeutics Committee. J Clin Endocrinol Metab 100:2192\u20132203. https:\/\/doi.org\/10.1210\/jc.2015-1002","journal-title":"J Clin Endocrinol Metab"},{"key":"148_CR8","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1159\/000452887","volume":"87","author":"MB Ranke","year":"2017","unstructured":"Ranke MB, Lindberg A, Tanaka T et al (2017) Baseline characteristics and gender differences in prepubertal children treated with growth hormone in Europe, USA, and Japan: 25 years\u2019 KIGS\u00ae experience (1987-2012) and review. Horm Res Paediatr 87:30\u201341. https:\/\/doi.org\/10.1159\/000452887","journal-title":"Horm Res Paediatr"},{"key":"148_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1687-9856-2013-9","volume":"2013","author":"PB Kaplowitz","year":"2013","unstructured":"Kaplowitz PB, Shulman DI, Frane JW et al (2013) Characteristics of children with the best and poorest first- and second-year growth during rhGH therapy: data from 25 years of the Genentech national cooperative growth study (NCGS). Int J Pediatr Endocrinol 2013:9. https:\/\/doi.org\/10.1186\/1687-9856-2013-9","journal-title":"Int J Pediatr Endocrinol"},{"key":"148_CR10","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1515\/jpem-2017-0489","volume":"31","author":"M Polak","year":"2018","unstructured":"Polak M, Konrad D, T\u00f8nnes Pedersen B et al (2018) Still too little, too late? Ten years of growth hormone therapy baseline data from the NordiNet\u00ae International Outcome Study. J Pediatr Endocrinol Metab 31:521\u2013532. https:\/\/doi.org\/10.1515\/jpem-2017-0489","journal-title":"J Pediatr Endocrinol Metab"},{"key":"148_CR11","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000435856","volume":"84","author":"AJ Swerdlow","year":"2015","unstructured":"Swerdlow AJ, Cooke R, Albertsson-Wikland K et al (2015) Description of the SAGhE cohort: a large European study of mortality and cancer incidence risks after childhood treatment with recombinant growth hormone. Horm Res Paediatr 84:172\u2013183. https:\/\/doi.org\/10.1159\/000435856","journal-title":"Horm Res Paediatr"},{"key":"148_CR12","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1001\/jama.2016.8708","volume":"316","author":"A Schoenfeld","year":"2016","unstructured":"Schoenfeld A, Redberg R (2016) The value of using registries to evaluate randomized clinical trial study populations. JAMA 316:1153\u20131154. https:\/\/doi.org\/10.1001\/jama.2016.8708","journal-title":"JAMA"},{"unstructured":"Humatrope 6mg powder and solvent for solution for injection - Summary of Product Characteristics (SmPC) - (eMC). https:\/\/www.medicines.org.uk\/emc\/product\/3780\/smpc . Accessed 14 Jul 2019","key":"148_CR13"},{"key":"148_CR14","doi-asserted-by":"publisher","first-page":"3990","DOI":"10.1210\/jcem.85.11.6984","volume":"85","author":"GH Research Society","year":"2000","unstructured":"GH Research Society (2000) Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. J Clin Endocrinol Metab 85:3990\u20133993. https:\/\/doi.org\/10.1210\/jcem.85.11.6984","journal-title":"J Clin Endocrinol Metab"},{"key":"148_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1542\/peds.109.1.45","volume":"109","author":"CL Ogden","year":"2002","unstructured":"Ogden CL, Kuczmarski RJ, Flegal KM et al (2002) Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. Pediatrics 109:45\u201360","journal-title":"Pediatrics"},{"key":"148_CR16","first-page":"378","volume-title":"Pediatric nephrology","author":"MA Preece","year":"1994","unstructured":"Preece MA (1994) Evaluation of growth and development. In: Holliday M, Barratt T, Avner E, Kogan B (eds) Pediatric nephrology, 3rd edn. Williams & Wilkins, Baltimore, pp 378\u2013396","edition":"3"},{"key":"148_CR17","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s40618-015-0418-0","volume":"39","author":"M Cappa","year":"2016","unstructured":"Cappa M, Iughetti L, Loche S et al (2016) Efficacy and safety of growth hormone treatment in children with short stature: the Italian cohort of the GeNeSIS clinical study. J Endocrinol Investig 39:667\u2013677. https:\/\/doi.org\/10.1007\/s40618-015-0418-0","journal-title":"J Endocrinol Investig"},{"key":"148_CR18","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1507\/endocrj.EJ11-0386","volume":"60","author":"S Tai","year":"2013","unstructured":"Tai S, Tanaka T, Hasegawa T et al (2013) An observational study of the effectiveness and safety of growth hormone (Humatrope(\u00ae)) treatment in Japanese children with growth hormone deficiency or Turner syndrome. Endocr J 60:57\u201364","journal-title":"Endocr J"},{"key":"148_CR19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.anpedi.2015.05.002","volume":"84","author":"C Luzuriaga Tom\u00e1s","year":"2016","unstructured":"Luzuriaga Tom\u00e1s C, Oyarzabal Irigoyen M, Caveda Cepas E et al (2016) Safety and efficacy of growth hormone treatment: GeNeSIS study in Spain. An Pediatr (Barc) 84:139\u2013147. https:\/\/doi.org\/10.1016\/j.anpedi.2015.05.002","journal-title":"An Pediatr (Barc)"},{"key":"148_CR20","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1159\/000350829","volume":"79","author":"C Deal","year":"2013","unstructured":"Deal C, Hasselmann C, Pf\u00e4ffle RW et al (2013) Associations between pituitary imaging abnormalities and clinical and biochemical phenotypes in children with congenital growth hormone deficiency: data from an international observational study. Horm Res Paediatr 79:283\u2013292. https:\/\/doi.org\/10.1159\/000350829","journal-title":"Horm Res Paediatr"},{"key":"148_CR21","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.beem.2015.04.009","volume":"29","author":"R Pf\u00e4ffle","year":"2015","unstructured":"Pf\u00e4ffle R (2015) Hormone replacement therapy in children: the use of growth hormone and IGF-I. Best Pract Res Clin Endocrinol Metab 29:339\u2013352. https:\/\/doi.org\/10.1016\/j.beem.2015.04.009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"148_CR22","doi-asserted-by":"publisher","first-page":"372","DOI":"10.9778\/cmajo.20180020","volume":"6","author":"C Deal","year":"2018","unstructured":"Deal C, Kirsch S, Chanoine J-P et al (2018) Growth hormone treatment of Canadian children: results from the GeNeSIS phase IV prospective observational study. C Open 6:372\u2013383. https:\/\/doi.org\/10.9778\/cmajo.20180020","journal-title":"C Open"},{"key":"148_CR23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1530\/acta.0.1270007","volume":"127","author":"JM Wit","year":"1992","unstructured":"Wit JM, Massarano AA, Kamp GA et al (1992) Growth hormone secretion in patients with Turner\u2019s syndrome as determined by time series analysis. Acta Endocrinol 127:7\u201312","journal-title":"Acta Endocrinol"},{"key":"148_CR24","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1210\/jcem.84.4.5634","volume":"84","author":"MB Ranke","year":"1999","unstructured":"Ranke MB, Lindberg A, Chatelain P et al (1999) Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. KIGS International Board. Kabi Pharmacia International Growth Study. J Clin Endocrinol Metab 84:1174\u20131183. https:\/\/doi.org\/10.1210\/jcem.84.4.5634","journal-title":"J Clin Endocrinol Metab"},{"key":"148_CR25","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1159\/000492397","volume":"90","author":"R Pf\u00e4ffle","year":"2018","unstructured":"Pf\u00e4ffle R, Land C, Sch\u00f6nau E et al (2018) Growth hormone treatment for short stature in the USA, Germany and France: 15 years of surveillance in the Genetics and Neuroendocrinology of Short-Stature International Study (GeNeSIS). Horm Res Paediatr 90:169\u2013180. https:\/\/doi.org\/10.1159\/000492397","journal-title":"Horm Res Paediatr"},{"key":"148_CR26","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1530\/eje.0.1410218","volume":"141","author":"Z Hochberg","year":"1999","unstructured":"Hochberg Z, Zadik Z (1999) Final height in young women with Turner syndrome after GH therapy: an open controlled study. Eur J Endocrinol 141:218\u2013224","journal-title":"Eur J Endocrinol"},{"key":"148_CR27","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1210\/jcem.84.12.6241","volume":"84","author":"TC Sas","year":"1999","unstructured":"Sas TC, de Muinck Keizer-Schrama SM, Stijnen T et al (1999) Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: results of a randomized dose-response trial. J Clin Endocrinol Metab 84:4607\u20134612. https:\/\/doi.org\/10.1210\/jcem.84.12.6241","journal-title":"J Clin Endocrinol Metab"},{"key":"148_CR28","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000085841","volume":"63","author":"YK van Pareren","year":"2005","unstructured":"van Pareren YK, Duivenvoorden HJ, Slijper FMEE et al (2005) Psychosocial functioning after discontinuation of long-term growth hormone treatment in girls with Turner syndrome. Horm Res 63:238\u2013244. https:\/\/doi.org\/10.1159\/000085841","journal-title":"Horm Res"},{"key":"148_CR29","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1210\/jcem.87.5.8477","volume":"87","author":"CA Quigley","year":"2002","unstructured":"Quigley CA, Crowe BJ, Anglin DG, Chipman JJ (2002) Growth hormone and low dose estrogen in Turner syndrome: results of a United States multi-center trial to near-final height. J Clin Endocrinol Metab 87:2033\u20132041. https:\/\/doi.org\/10.1210\/jcem.87.5.8477","journal-title":"J Clin Endocrinol Metab"},{"key":"148_CR30","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1159\/000358198","volume":"81","author":"J L\u00e9ger","year":"2014","unstructured":"L\u00e9ger J, Olivieri A, Donaldson M et al (2014) European Society for Paediatric Endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism. Horm Res Paediatr 81:80\u2013103. https:\/\/doi.org\/10.1159\/000358198","journal-title":"Horm Res Paediatr"},{"issue":"5","key":"148_CR31","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1530\/EJE-16-1024","volume":"177","author":"Michel Polak","year":"2017","unstructured":"Polak M, Blair JC, Kotnik P, et al (2017) Early growth hormone treatment start in childhood growth hormone deficiency improves near adult height: analysis from NordiNet(\u00ae) International Outcome Study. Eur J Endocrinol EJE-16-1024. https:\/\/doi.org\/10.1530\/EJE-16-1024","journal-title":"European Journal of Endocrinology"},{"key":"148_CR32","doi-asserted-by":"publisher","first-page":"4212","DOI":"10.1210\/jcem.85.11.6976","volume":"85","author":"MB Ranke","year":"2000","unstructured":"Ranke MB, Lindberg A, Chatelain P et al (2000) Prediction of long-term response to recombinant human growth hormone in Turner syndrome: development and validation of mathematical models. J Clin Endocrinol Metab 85:4212\u20134218. https:\/\/doi.org\/10.1210\/jcem.85.11.6976","journal-title":"J Clin Endocrinol Metab"},{"key":"148_CR33","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/j.1365-2265.2011.03937.x","volume":"74","author":"IP Hughes","year":"2011","unstructured":"Hughes IP, Choong CS, Harris M et al (2011) Growth hormone treatment for Turner syndrome in Australia reveals that younger age and increased dose interact to improve response. Clin Endocrinol 74:473\u2013480. https:\/\/doi.org\/10.1111\/j.1365-2265.2011.03937.x","journal-title":"Clin Endocrinol"},{"key":"148_CR34","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1515\/JPEM.2007.20.6.685","volume":"20","author":"C Land","year":"2007","unstructured":"Land C, Blum WF, Shavrikova E et al (2007) Predicting the growth response to growth hormone (GH) treatment in prepubertal and pubertal children with isolated GH deficiency--model validation in an observational setting (GeNeSIS). J Pediatr Endocrinol Metab 20:685\u2013693","journal-title":"J Pediatr Endocrinol Metab"},{"key":"148_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6947-9-1","volume":"9","author":"B Kristr\u00f6m","year":"2009","unstructured":"Kristr\u00f6m B, Dahlgren J, Niklasson A et al (2009) The first-year growth response to growth hormone treatment predicts the long-term prepubertal growth response in children. BMC Med Inform Decis Mak 9:1. https:\/\/doi.org\/10.1186\/1472-6947-9-1","journal-title":"BMC Med Inform Decis Mak"},{"key":"148_CR36","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/j.1651-2227.1999.tb14420.x","volume":"88","author":"M Ranke","year":"1999","unstructured":"Ranke M, Lindberg A, Chatelain P et al (1999) Predicting the response to recombinant human growth hormone in Turner syndrome: KIGS models. Acta Paediatr 88:122\u2013125. https:\/\/doi.org\/10.1111\/j.1651-2227.1999.tb14420.x","journal-title":"Acta Paediatr"},{"key":"148_CR37","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1530\/EJE-15-0873","volume":"174","author":"DB Allen","year":"2016","unstructured":"Allen DB, Backeljauw P, Bidlingmaier M et al (2016) GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults. Eur J Endocrinol 174:P1\u2013P9. https:\/\/doi.org\/10.1530\/EJE-15-0873","journal-title":"Eur J Endocrinol"},{"key":"148_CR38","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1515\/JPEM.2011.319","volume":"24","author":"R Noto","year":"2011","unstructured":"Noto R, Maneatis T, Frane J et al (2011) Intracranial hypertension in pediatric patients treated with recombinant human growth hormone: data from 25 years of the Genentech National Cooperative Growth Study. J Pediatr Endocrinol Metab 24:627\u2013631","journal-title":"J Pediatr Endocrinol Metab"},{"key":"148_CR39","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s11832-013-0493-8","volume":"7","author":"M Witbreuk","year":"2013","unstructured":"Witbreuk M, van Kemenade FJ, van der Sluijs JA et al (2013) Slipped capital femoral epiphysis and its association with endocrine, metabolic and chronic diseases: a systematic review of the literature. J Child Orthop 7:213\u2013223. https:\/\/doi.org\/10.1007\/s11832-013-0493-8","journal-title":"J Child Orthop"},{"key":"148_CR40","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1210\/jc.2002-020542","volume":"88","author":"M Bramnert","year":"2003","unstructured":"Bramnert M, Segerlantz M, Laurila E et al (2003) Growth hormone replacement therapy induces insulin resistance by activating the glucose-fatty acid cycle. J Clin Endocrinol Metab 88:1455\u20131463. https:\/\/doi.org\/10.1210\/jc.2002-020542","journal-title":"J Clin Endocrinol Metab"},{"key":"148_CR41","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1210\/jc.2018-01189","volume":"104","author":"CJ Child","year":"2019","unstructured":"Child CJ, Zimmermann AG, Chrousos GP et al (2019) Safety outcomes during pediatric GH therapy: final results from the prospective GeNeSIS observational program. J Clin Endocrinol Metab 104:379\u2013389. https:\/\/doi.org\/10.1210\/jc.2018-01189","journal-title":"J Clin Endocrinol Metab"},{"key":"148_CR42","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jaut.2012.01.015","volume":"38","author":"VK Bakalov","year":"2012","unstructured":"Bakalov VK, Gutin L, Cheng CM et al (2012) Autoimmune disorders in women with Turner syndrome and women with karyotypically normal primary ovarian insufficiency. J Autoimmun 38:315\u2013321. https:\/\/doi.org\/10.1016\/j.jaut.2012.01.015","journal-title":"J Autoimmun"},{"key":"148_CR43","first-page":"765","volume":"21","author":"JY Kim","year":"2001","unstructured":"Kim JY, Rosenfeld SR, Keyak JH (2001) Increased prevalence of scoliosis in Turner syndrome. J Pediatr Orthop 21:765\u2013766","journal-title":"J Pediatr Orthop"},{"key":"148_CR44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1748-7161-2-3","volume":"2","author":"GA Day","year":"2007","unstructured":"Day GA, McPhee IB, Batch J, Tomlinson FH (2007) Growth rates and the prevalence and progression of scoliosis in short-statured children on Australian growth hormone treatment programmes. Scoliosis 2:3. https:\/\/doi.org\/10.1186\/1748-7161-2-3","journal-title":"Scoliosis"},{"key":"148_CR45","first-page":"CD003887","volume-title":"Cochrane database of systematic reviews","author":"L Baxter","year":"2007","unstructured":"Baxter L, Bryant J, Cave CB, Milne R (2007) Recombinant growth hormone for children and adolescents with Turner syndrome. In: Bryant J (ed) Cochrane database of systematic reviews. John Wiley & Sons, Ltd, Chichester, p CD003887"},{"key":"148_CR46","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1210\/jc.2007-1723","volume":"93","author":"K Bolar","year":"2008","unstructured":"Bolar K, Hoffman AR, Maneatis T, Lippe B (2008) Long-term safety of recombinant human growth hormone in Turner syndrome. J Clin Endocrinol Metab 93:344\u2013351. https:\/\/doi.org\/10.1210\/jc.2007-1723","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"148_CR47","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1210\/jc.2017-00214","volume":"102","author":"Charmian A Quigley","year":"2017","unstructured":"Quigley CA, Child CJ, Zimmermann AG et al (2017) Mortality in children receiving growth hormone treatment for growth disorders: data from the GeNeSIS observational program. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/jc.2017-00214","journal-title":"The Journal of Clinical Endocrinology & Metabolism"}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-019-00148-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s42000-019-00148-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-019-00148-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T20:31:58Z","timestamp":1664829118000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s42000-019-00148-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,6]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["148"],"URL":"https:\/\/doi.org\/10.1007\/s42000-019-00148-y","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"type":"print","value":"1109-3099"},{"type":"electronic","value":"2520-8721"}],"subject":[],"published":{"date-parts":[[2019,11,6]]},"assertion":[{"value":"20 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"A.K and D.E. are employed by Pharmaserve Lilly SACI. The GeNeSIS study was sponsored by Eli-Lilly.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}